AstraZeneca: positive data against the big C
(CercleFinance.com) - On Sunday AstraZeneca presented positive data for its three main anti-cancer drugs at the European Society for Medical Oncology (ESMO) congress, which is currently being held in Paris.
In particular, the biopharmaceutical group unveiled detailed results from a phase II study of Enhertu, the antibody conjugate it is developing with Japan's Daiichi Sankyo, which showed a "significant" tumour response in patients with non-operable and/or metastatic non-small cell lung cancer.
Also at ESMO, the company reported Phase III results for Tagrisso showing a clinically significant improvement in disease-free survival in patients with early stage non-small cell lung cancer.
Finally, phase III data for Imfinzi showed a marked improvement in overall survival in patients with stage 4 non-small cell lung cancer.
However, London listed AstraZeneca shares were pretty flat on Monday morning following these announcements, in a market that was up over 1%.
Copyright (c) 2022 CercleFinance.com. All rights reserved.
In particular, the biopharmaceutical group unveiled detailed results from a phase II study of Enhertu, the antibody conjugate it is developing with Japan's Daiichi Sankyo, which showed a "significant" tumour response in patients with non-operable and/or metastatic non-small cell lung cancer.
Also at ESMO, the company reported Phase III results for Tagrisso showing a clinically significant improvement in disease-free survival in patients with early stage non-small cell lung cancer.
Finally, phase III data for Imfinzi showed a marked improvement in overall survival in patients with stage 4 non-small cell lung cancer.
However, London listed AstraZeneca shares were pretty flat on Monday morning following these announcements, in a market that was up over 1%.
Copyright (c) 2022 CercleFinance.com. All rights reserved.